# EDGAR Filing Document

**Accession Number:** 0001868279
**File Stem:** 0001104659-26-050344
**Filing Date:** 2026-4
**Character Count:** 4695
**Document Hash:** 8e64a2397e4399d494d53d3462715a3d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-050344.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0001104659-26-050344

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260428

**DATE AS OF CHANGE**: 20260428

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ArriVent BioPharma, Inc.
- **CENTRAL INDEX KEY:** 0001868279
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41929
- **FILM NUMBER:** 26907819

**BUSINESS ADDRESS:**
- **STREET 1:** 18 CAMPUS BLVD.
- **STREET 2:** SUITE 100
- **CITY:** NEWTOWN SQUARE
- **STATE:** PA
- **ZIP:** 19073-3269
- **BUSINESS PHONE:** 240-780-6356

**MAIL ADDRESS:**
- **STREET 1:** 18 CAMPUS BLVD.
- **STREET 2:** SUITE 100
- **CITY:** NEWTOWN SQUARE
- **STATE:** PA
- **ZIP:** 19073-3269

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ArriVent Biopharma, Inc.
- **DATE OF NAME CHANGE:** 20210617

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington** **, D.C. 20549**

**SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No.)

Filed by the Registrant ⌧

Filed by a Party other than the Registrant ◻

Check the appropriate box:

---

| | |
|:---|:---|
| ◻ | Preliminary Proxy Statement |
| ◻ | **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** |
| ◻ | Definitive Proxy Statement |
| ⌧ | Definitive Additional Materials |
| ◻ | Soliciting Material Under §240.14a-12 |

---

**ArriVent BioPharma, Inc.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

⌧ No fee required <br> ◻ Fee paid previously with preliminary materials <br> ◻ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm261626d3_defa14aimg01.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V96463-P51036 ARRIVENT BIOPHARMA, INC. 18 CAMPUS BOULEVARD SUITE 100 NEWTOWN SQUARE, PENNSYLVANIA 19073 UNITED STATES ARRIVENT BIOPHARMA, INC. 2026 Annual Meeting Vote by June 17, 2026 11:59 PM ET You invested in ARRIVENT BIOPHARMA, INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 18, 2026. Vote Virtually at the Meeting\* June 18, 2026 12:00 p.m. Eastern Time Virtually at: www.virtualshareholdermeeting.com/AVBP2026 \*Please check the meeting materials for any special requirements for meeting attendance. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 4, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm261626d3_defa14aimg02.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings". Voting Items Board Recommends V96464-P51036 1. Election of Directors For Nominees: 01) James Healy, M.D., Ph.D. 02) John Hohneker, M.D. 03) Stuart Lutzker, M.D., Ph.D. 2. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof. THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. |

---